N.H. Code Admin. R. Nat 406.01 : Naturopathic Board of Examiners — CONTINUED STATUS — FORMULARY — Formulary TEXT PDF Pursuant to RSA 328-E:16, III, the formulary for licensees shall be as follows: (a) Amino acids and peptides, including but not limited to: (1) Acetyl Carnitine; (2) EDTA; (3) GABA; (4) Glutathione; (5) Levocarnitine; 6) Succinic Acid (DMSA); and (7) Tryptophan; (b) Animal preparations and their derivatives, including but not limited to: (1) Adrenal; (2) Thymus; (3) Thyroid; (4) Fish oils, including derived mega-3 fatty acids such as Ethyl eicosapentaenoic acid, docosahexaenoic acid, and omega-3 carboxylic acids; (5) Hyaluronic acid; and (6) Bile acids, including deoxycholic acid; (c) The following anti-gout agents: (1) Allopurinol; (2) Colchicine; and (3) Probenecid; (d) H 1 and H 2 antihistamine-class agents; (e) The following anti-leukotriene agents: (1) Montelukast; and (2) Zafirlukast; (f) The following anti-hyperglycemic agents: (1) The alpha glucosidase inhibitor Acarbose; (2) The biguanide Metformin; (3) Sulfonylurea-class agents; (4) Thiazolidinedione-class agents (TZDs); (5) Sodium-glucose transport protein 2 (SGLT-2) inhibitors; (6) Dipeptidyl peptidase 4 (DPP-4) inhibitors; (7) Glucagon-like peptide-1 (GLP-1) receptor agonists; and (8) Synthetic and human insulin; (g) The following anti-infective agents: (1) The following antibacterial agents: a. Aminoglycosides, including but not limited to: 1. Gentamicin; 2. Kanamycin sulfate; and 3. Tobramycin; b. The following beta-lactam antibiotics: 1. Cephalosporins, including but not limited to: (i) Cefaclor; (ii) Cefadroxil; (iii) Cefdinir; (iv) Ceditoren; (v) Cefibuten; (vi) Cefixime; (vii) Cefonicid sodium; (viii) Cepodoxime proxetil; (ix) Cefprozil; (x) Ceftibuten; (xi) Cefuroxime; (xii) Cephalexin; and (xiii) Cephradine; and 2. Penicillins, including but not limited to: (i) Amoxicillin and clavulanate; (ii) Amoxicillin; (iii) Ampicillin and sulbactam; (iv) Ampicillin; (v) Bacampicillin; (vi) Cloxacillin; (vii) Dicloxacillin; (viii) Oxacillin; and (ix) Penicillin; c. Macrolides and ketolides, including but not limited to: 1. Azithromycin; 2. Clarithromycin; 3. Dirithromycin; 4. Erythromycins; 5. Telithromycin; and 6. Troleandomycin; d. Quinolones, including but not limited to: 1. Ciprofloxacin; 2. Levofloxacin; and 3. Ofloxacin; e. The following sulfonamides: 1. Sulfonamide; 2. Sofamethoxazole; 2. Trimethoprim; and 3. Dapsone; f. Tetracyclines, including but not limited to: 1. Demeclocycline hydrochloride; 2. Doxycycline; 3. Minocycline; 4. Oxytetracycline; and 5. Tetracycline; g. The following miscellaneous antibacterials: 1. Bacitracin; 2. Clindamycin; 3. Colistimethate; 4. Lincomycin; 5. Novobiocin; 6. Polymyxin B Sulfate; 7. Spectinomycin; 8. Vancomycin; 9. Daptomycin; and (2) Antifungals, such as: a. Polyene; b. Amphotericin B; c. Nystatin; d. Fluconazole; e. Ketoconazole; f. Clotrimazole; g. Terbinafine; and h. Itraconazole; (3) The following anti-virals: a. Valcyclovir; b. Acyclovir; c. Famciclovir; and d. Oseltamivir; (4) Anti-helmetics, such as: a. Mebendazole; b. Thiabendazole; c. Nitazoxanide; d. Albendazole; e. Ivermectin; and f. Praziquantel; (5) The following antitubercular and antimycobacterial agents: a. Aminosalicylic acid; b. Cycloserine; c. Pyrazinamidel d. Rifabutin; and e. Rifampin; (6) The following antiprotozoal and antiparasitic agents: a. The halogenated 8-hydroxyquinoline iodoquinol; b. The following nitroimidazoles: 1. Metronidazole; and 2. Tinidazole; c. The following quinolines: 1. Chloroquine; 2. Hydroxychloroquine; 3. Mefloquine; and 4. Quinine sulfate; and d. The hydroxynaphthoquinone atovaquone; and (7) The following miscellaneous anti-infective agents: a. Mupirocin; b. Permethrin; and c. Pyrethrins; (h) The following anti-thyroid agent thionamides (thioureylenes) : (1) Methimazole; and (2) Propylthiouracil; (i) The following autonomic agents: (1) The following cholinergic agents: a. The following antimuscarinic agents: 1. Atropine; 2. Atropine sulfate; 3. Belladonna; 4. Flavoxate; 5. Homatropine hydrobromide; 6. Hyoscyamine; 7. Methscopolamine; and 8. Scopolamine; b. The muscarinic receptor agonist pilocarpine; c. Nicotinic receptor agonists: 1. Nicotine; and 2. Varenicline; and d. The following acetylcholinesterase inhibitors: 1. Donepezil; 2. Galantamine; and 3. Rivastigmine; (2) The following ergot derivatives: a. Ergonovine maleate; and b. Methergine; (3) The following sympathomimetics: a. Ephedrine; b. Epinephrine, including autoinject forms; c. Pseudoephedrine; d. Midodrine; e. Clonidine; f. Guanfacine; g. Albuterol; h. Formoterol; and i. Salmetrol; (4) The following sympatholytic agents: a. The following alpha adrenergic blocking agents: 1. Yohimbine; and 2. Tamulosin; and b. Beta adrenergic blocking agents, including but not limited to: 1. Atenolol; 2. Bisoprolol; 3. Metoprolol; 4. Propranolol; and 5. Timolol; and (5) The following agents for ADHD/Narcolepsy treatment: a. Methylphenidate; b. Dexmethylphenidate; c. Amphetamine/dextroamphetamine; d. Dextroamphetamine; e. Lisdexamfetamine; f. Atomoxetine; and g. Modafinil; (j) The following biologicals: (1) The following biological response modifiers: a. Candida and tricophyton extracts; and b. Rho(D) immune globulins; (2) The following skin test antigens: a. Purified protein derivative tuberculin tests; b. Candida albicans skin test antigen; and c. Coccidioides immitis spherule derived skin test antigen; (3) Blood typing serum; (4) Blood and tissue derived products; (5) Enzymes, including but not limited to: a. Amylase; b. Collagenase; c. Desoxyribonuclease; d. Fribinolysin; e. Hyaluronidase; f. Lipase; g. Pancrelipase; and h. Papain; (6) Electrolytes and fluid replacements, including but not limited to: a. Saline solutions; b. Sterile water; c. D5W; d. Lactated ringers solution; and e. Sodium bicarbonate; (7) Hormones as described in Nat 406.01(p); (8) Immune globulins; (9) Prostaglandins and prostaglandin analogs, including but not limited to: a. Alprostadil; b. Bimatoprost; c. Dinoprostone; d. Iloprost; and e. Misoprostal; and (10) Botolinum toxin derivatives: a. Onabotilinumtoxin A; b. Abobotulinumtoxin A; and c. Incobotilinumtoxin A; (k) Botanical preparations, with the following exceptions:: (1) Legend or controlled Digitalis species derivatives; (2) Legend or controlled Coca species derivatives; (3) Legend or controlled Vinca species derivatives; (4) Legend or controlled Taxus species derivatives; (5) Legend or controlled Rauwolfia species derivatives; and (6) Derivatives of Papaver somniferum unless otherwise specified; (l) The following cardiovascular agents: (1) The following antilipemics: a. HMG CoA reductase inhibitors, such as: 1. Atorvastatin; 2. Fluvastatin; 3. Lovastatin; 4. Pravastatin; and 5. Simvastatin; b. Cholestyramine; and c. Colesevelam; (2) The following anti-angina, piperazine derivative, metabolism modifiers, or p-FOX inhibitors; a. Ranolazine; and b. Trimetazidine; (3) The following anti-angina nitrates: a. Nitroglycerin; b. Isosorbide dinatrate; and c. Isosobide mononitrate; (4) Dihydropyridine-class calcium channel blockers; (5) The following non-dihydropyridine calcium channel blockers: a. Diltiazem; and b. Verapamil; (6) Angotensin converting enzyme inhibitors; (7) Angiotensin II receptor blockers; (8) The following diuretics: a. Chlorthalidone; b. Hydrochlorothiazide; c. Epleronone; and d. Spironolactone; and (9) The following anti-coagulant agents: a. Heparin for in-office use; b. Heparin flushes; c. Warfarin; d. Apixaban; and e. Rivaroxaban; (m) The following central nervous system agents: (1) The following anticonvulsant and antipeptic agents: a. Gabapentin; b. Tiagabine; c. Pregabalin; d. Carbamazepine; e. Oxcarbazepine; f. Lamotrigine; and g. Toiramate; (2) The following antispasmodics: a. Baclofen; b. Cyclobenzaprine; c. Methocarbamol; and d. Tizanidine; (3) The following anxiolytics, sedatives and hypnotics: 1. The following benzodiazepines; a. Alprozolam; b. Chlordiazepoxide; c. Clobazam; d. Clonazepam; e. Diazepam; f. Lorazepam; and g. Temazapam; 2. The following non-benzodiazepine sedative-hypnotic agents: a. The imidazopyridine agent Zolpidem; b. The cyclopyrrolone agent Eszopiclone; c. Suvorexant; and d. Ramelteon; 3. The anti-manic agent Lithium; and 4. The anxiolytic Buspirone; and (4) Antidepressants for FDA approved age groups: a. The following selective serotonin reuptake inhibitors (SSRIs): 1. Citalopram; 2. Escitalopram; 3. Fluoxetine; 4. Paroxetine; and 5. Sertraline; b. Serotonin-norepinephirene reuptake inhibitors (SNRIs): 1. Duloxetine; 2. Desvenlafaxine; and 3. Venlafaxine; and c. The following tricyclic antidepressants (TCAs): 1. Amitriptyline; 2. Doxepin; 3. Imipramine; 4. Nortriptyline; and 5. Clomipramine; (n) The following erectile dysfunction agents: (1) Tadalafil; and (2) Sildenafil; (o) Homeopathic preparations and their derivatives including both sterile injectable and non-injectable dosage forms; (p) Hormones such as: (1) Adrenal hormones, such as: a. Aldosterone; b. DHEA; c. Epinephrine; d. Pregnenalone; and e. Synthetic glucocorticoids such as: 1. Betamethasone; 2. Cortisone acetate; 3. Dexamethasone; 4. Triamcinolone and Triamcinolone acetonide; 5. Methylprednisolone and Prednisolone; 6. Prednisone; and 7. Hydrocortisone; (2) Selective estrogen-receptor modulators (SERMs), and anti-estrogens or estrogen antagonists, such as: 1. Clomiphene; 2. Tamoxifen; 3. Toremifene; and 4. Raloxifene; and (3) Gonadal hormones, such as: a. Conjugated estrogens; b. Estrogen; c. Estradiol; d. Estriol; e. Estrone; f. Estropipate; g. Ethinyl estradiol; h. HCG; i. Progesterone; j. Quinestrol; and k. Testosterone; (4) Thyroid hormones, such as: a. Levothyroxine; b. Liothyronine; c. Natural dessicated thyroid hormones; and d. Calcium; (5) Pituitary hormones, such as: a. ACTH; b. Growth hormones; and c. Oxytocin; and (6) Hormonal modifiers, such as: a. Dutasteride; b. Finasteride; and c. Anastrazole; (q) Antitussives, such as: (1) Codeine for cough; (2) Guafenesin; and (3) Benzonatate; (r) Local anesthetics, including both injectable and non-injectable dosage form such as: (1) Amino esters for in-office use: a. Procaine; b. Chloroprocaine; c. Tetracaine; and d. Benzocaine; (2) Amino amides, for in-office use: a. Lidocaine; b. Mepivocaine; c. Bupivacaine; d. Levobupacaine; e. Etidocaine; and f. Prilocaine; (3) The following other topical anesthetics: a. The ketone Dyclonine, for in-office use; b. The ether Pramoxine; c. The skin refrigerant ethyl chloride, also known as chloroethane; and d. Topical lidocaine; and (4) The methyl group donor betaine; (s) Anti-psoriatic agents for topical use only: (1) Dithranol (anthralin); (2) Calcipotriene; (3) Fluocinonide; and (4) Tacrolimus; (t) Minerals, trace minerals, and their derivatives, such as super saturated potassium iodine (SSKI); (u) The following miscellaneous agents: (1) Acamprosate; (2) Acetazolamide; (3) Bee venom; (4) Crofelemer; (5) Cromolyn sodium; (6) DMPS; (7) DMSO; (8) Ethyl Chloride spray; (9) Fluro-ethyl spray; (10) Fluro-methane spray; (11) Hydrogen peroxide; (12) Hydrochloric acid; (13) Methylsulfonylmethane; (14) Ondansetron; (15) Oxygen; (16) Ozone; (17) Poly-L-lactic acid and derivatives; (18) Salicylates, propionic acid, and acetic acid derivatives such as: a. Mesalamine; b. Topical salicyclic acid preparations; c. Indomethacin; d. Ibuprofen; e. Naproxen; f. Ketorolac; and g. Diclofenac; and (19) Urea; (v) In-office medical equipment, medical devices, and therapeutic devices such as: (1) Needles; (2) Syringes; (3) IV Tubing; (4) Filters; (5) The following barrier contraceptives: a. Cervical caps; and b. Diaphragms, excluding intrauterine devices; (6) Nebulizers, inhalers, spacers, actuators, and mouthpieces for medication delivery; (7) CPAP machies and medical devices for the treatment and prevention of sleep apnea; and (8) Auditory devices. (w) Agents needed to carry out diagnostic tests or physiological function tests such as: (1) Mannitol; (2) Methacholine; (3) Dexamethasone; (4) Dyes and contrasts such as: a. Imaging contrasts; b. Methylene blue; and c. Triple dye; (x) Vaccinations, provided they are for use and not prescription, including but not limited to: (1) BCG; (2) Cholera; (3) Diphtheria; (4) DPT; (5) Haemophilus b Conjugate; (6) Hepatitus A Virus; (7) Hepatitus B; (8) Influenza Virus; (9) Japanese Encaphalitis Virus; (10) Measles Virus; (11) Mumps virus; (12) Pertussis; (13) Plague; (14) Pneumococcal; (15) Polio virus - inactivated; (16) Poliovirus - live oral; (17) Rabies; (18) Rubella; (19) Smallpox; (20) Tetanus IG; (21) Tetanus Toxoid; (22) Typhoid; (23) Varicella; (24) Yellow fever; and (25) Covid-19. (y) All forms of prescription and non-prescription vitamin preparations and their derivatives, except for Isotretinoin; and (z) Anti-addictive agents: (1) Disulfiram; (2) Naltrexone; and (3) Naloxone. N.H. Code Admin. R. Nat 406.01 #8679, eff 7-11-06; ss by #9656, eff 2-13-10 Amended by Volume XXXVII Number 23, Filed June 8, 2017, Proposed by #12176, Effective 5/17/2017, Expires 5/17/2027. Amended by Volume XL Number 41, Filed October 8, 2020, Proposed by # 13112, Effective 9/24/2020, Expires 9/24/2030.